Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs

A. S. Moore, A. E. Frimberger, N. Sullivan, Peter F Moore

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: Splenic fibrohistiocytic nodules (SFHN) are commonly diagnosed. It is suspected that these represent a heterogeneous group of malignant and nonmalignant diseases, separation of which could improve the ability of clinicians to prognosticate for dogs. Hypothesis/Objectives: Immunohistochemistry will differentiate histologic diagnoses within the group of SFHN; survival after splenectomy is associated with those histologic types. Animals: Thirty-two dogs with SFHN treated by or under direction from veterinary oncologists. Methods: Retrospective case record analysis from dogs followed from splenectomy until death. Clinical, histopathologic, and immunohistochemistry data analyzed for an association with survival time. Results: Thirty-two dogs had SFHN; grade 1 (2 dogs), grade 2 (9 dogs), and grade 3 (lymphoid percentage <40%; 21 dogs). Twenty-two dogs died, 10 were censored (9 alive median of 883 days after splenectomy). Median overall survival was 387 days, and grade 3 SFHN was positively associated with survival time as previously reported (P < .001). Of 31 available samples, dogs had diseases reclassified as nodular hyperplasia (13; 8 complex, 5 lymphoid including 2 marginal zone), lymphoma (4; 2 marginal zone lymphoma, 1 high grade B-cell lymphoma, and 1 marginal zone transitional to high grade B-cell lymphoma), 8 stromal sarcomas, and 6 histiocytic sarcomas. Dogs with histiocytic sarcoma had worse survival (median 74 days) than dogs with other diseases. Conclusions and Clinical Importance: Splenic histiocytic sarcoma is an aggressive disease; however, some dogs with stromal sarcomas had long survival times. The term SFHN is no longer warranted for this group of disorders.

Original languageEnglish (US)
Pages (from-to)1164-1168
Number of pages5
JournalJournal of Veterinary Internal Medicine
Volume26
Issue number5
DOIs
StatePublished - Sep 2012

Fingerprint

Dogs
dogs
sarcoma
Histiocytic Sarcoma
lymphoma
Splenectomy
B-Cell Lymphoma
Sarcoma
Non-Hodgkin's Lymphoma
B-lymphocytes
immunohistochemistry
Lymphoma
Immunohistochemistry
Dog Diseases
dog diseases
hyperplasia
Hyperplasia
death
animals

Keywords

  • Cancer
  • Chemotherapy
  • Histiocytic sarcoma
  • Oncology

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs. / Moore, A. S.; Frimberger, A. E.; Sullivan, N.; Moore, Peter F.

In: Journal of Veterinary Internal Medicine, Vol. 26, No. 5, 09.2012, p. 1164-1168.

Research output: Contribution to journalArticle

Moore, A. S. ; Frimberger, A. E. ; Sullivan, N. ; Moore, Peter F. / Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs. In: Journal of Veterinary Internal Medicine. 2012 ; Vol. 26, No. 5. pp. 1164-1168.
@article{b748eaa18d464612824c5ed6e8e5dde4,
title = "Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs",
abstract = "Background: Splenic fibrohistiocytic nodules (SFHN) are commonly diagnosed. It is suspected that these represent a heterogeneous group of malignant and nonmalignant diseases, separation of which could improve the ability of clinicians to prognosticate for dogs. Hypothesis/Objectives: Immunohistochemistry will differentiate histologic diagnoses within the group of SFHN; survival after splenectomy is associated with those histologic types. Animals: Thirty-two dogs with SFHN treated by or under direction from veterinary oncologists. Methods: Retrospective case record analysis from dogs followed from splenectomy until death. Clinical, histopathologic, and immunohistochemistry data analyzed for an association with survival time. Results: Thirty-two dogs had SFHN; grade 1 (2 dogs), grade 2 (9 dogs), and grade 3 (lymphoid percentage <40{\%}; 21 dogs). Twenty-two dogs died, 10 were censored (9 alive median of 883 days after splenectomy). Median overall survival was 387 days, and grade 3 SFHN was positively associated with survival time as previously reported (P < .001). Of 31 available samples, dogs had diseases reclassified as nodular hyperplasia (13; 8 complex, 5 lymphoid including 2 marginal zone), lymphoma (4; 2 marginal zone lymphoma, 1 high grade B-cell lymphoma, and 1 marginal zone transitional to high grade B-cell lymphoma), 8 stromal sarcomas, and 6 histiocytic sarcomas. Dogs with histiocytic sarcoma had worse survival (median 74 days) than dogs with other diseases. Conclusions and Clinical Importance: Splenic histiocytic sarcoma is an aggressive disease; however, some dogs with stromal sarcomas had long survival times. The term SFHN is no longer warranted for this group of disorders.",
keywords = "Cancer, Chemotherapy, Histiocytic sarcoma, Oncology",
author = "Moore, {A. S.} and Frimberger, {A. E.} and N. Sullivan and Moore, {Peter F}",
year = "2012",
month = "9",
doi = "10.1111/j.1939-1676.2012.00986.x",
language = "English (US)",
volume = "26",
pages = "1164--1168",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Histologic and Immunohistochemical Review of Splenic Fibrohistiocytic Nodules in Dogs

AU - Moore, A. S.

AU - Frimberger, A. E.

AU - Sullivan, N.

AU - Moore, Peter F

PY - 2012/9

Y1 - 2012/9

N2 - Background: Splenic fibrohistiocytic nodules (SFHN) are commonly diagnosed. It is suspected that these represent a heterogeneous group of malignant and nonmalignant diseases, separation of which could improve the ability of clinicians to prognosticate for dogs. Hypothesis/Objectives: Immunohistochemistry will differentiate histologic diagnoses within the group of SFHN; survival after splenectomy is associated with those histologic types. Animals: Thirty-two dogs with SFHN treated by or under direction from veterinary oncologists. Methods: Retrospective case record analysis from dogs followed from splenectomy until death. Clinical, histopathologic, and immunohistochemistry data analyzed for an association with survival time. Results: Thirty-two dogs had SFHN; grade 1 (2 dogs), grade 2 (9 dogs), and grade 3 (lymphoid percentage <40%; 21 dogs). Twenty-two dogs died, 10 were censored (9 alive median of 883 days after splenectomy). Median overall survival was 387 days, and grade 3 SFHN was positively associated with survival time as previously reported (P < .001). Of 31 available samples, dogs had diseases reclassified as nodular hyperplasia (13; 8 complex, 5 lymphoid including 2 marginal zone), lymphoma (4; 2 marginal zone lymphoma, 1 high grade B-cell lymphoma, and 1 marginal zone transitional to high grade B-cell lymphoma), 8 stromal sarcomas, and 6 histiocytic sarcomas. Dogs with histiocytic sarcoma had worse survival (median 74 days) than dogs with other diseases. Conclusions and Clinical Importance: Splenic histiocytic sarcoma is an aggressive disease; however, some dogs with stromal sarcomas had long survival times. The term SFHN is no longer warranted for this group of disorders.

AB - Background: Splenic fibrohistiocytic nodules (SFHN) are commonly diagnosed. It is suspected that these represent a heterogeneous group of malignant and nonmalignant diseases, separation of which could improve the ability of clinicians to prognosticate for dogs. Hypothesis/Objectives: Immunohistochemistry will differentiate histologic diagnoses within the group of SFHN; survival after splenectomy is associated with those histologic types. Animals: Thirty-two dogs with SFHN treated by or under direction from veterinary oncologists. Methods: Retrospective case record analysis from dogs followed from splenectomy until death. Clinical, histopathologic, and immunohistochemistry data analyzed for an association with survival time. Results: Thirty-two dogs had SFHN; grade 1 (2 dogs), grade 2 (9 dogs), and grade 3 (lymphoid percentage <40%; 21 dogs). Twenty-two dogs died, 10 were censored (9 alive median of 883 days after splenectomy). Median overall survival was 387 days, and grade 3 SFHN was positively associated with survival time as previously reported (P < .001). Of 31 available samples, dogs had diseases reclassified as nodular hyperplasia (13; 8 complex, 5 lymphoid including 2 marginal zone), lymphoma (4; 2 marginal zone lymphoma, 1 high grade B-cell lymphoma, and 1 marginal zone transitional to high grade B-cell lymphoma), 8 stromal sarcomas, and 6 histiocytic sarcomas. Dogs with histiocytic sarcoma had worse survival (median 74 days) than dogs with other diseases. Conclusions and Clinical Importance: Splenic histiocytic sarcoma is an aggressive disease; however, some dogs with stromal sarcomas had long survival times. The term SFHN is no longer warranted for this group of disorders.

KW - Cancer

KW - Chemotherapy

KW - Histiocytic sarcoma

KW - Oncology

UR - http://www.scopus.com/inward/record.url?scp=84866311830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866311830&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2012.00986.x

DO - 10.1111/j.1939-1676.2012.00986.x

M3 - Article

C2 - 22882592

AN - SCOPUS:84866311830

VL - 26

SP - 1164

EP - 1168

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -